NYSE:WAT - Waters Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $251.25
Forecasted Upside: -26.63 %
Number of Analysts: 11
Breakdown:
3 Sell Ratings
7 Hold Ratings
1 Buy Ratings
0 Strong Buy Ratings

^$342.44 As of 06/21/2021 05:46 PM ET

▼ -0.27 (-0.08%)

1 month | 3 months | 12 months

Get New Waters Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for WAT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for WAT

^$251.25

▼ -26.63% Downside Potential

This price target is based on 11 analysts offering 12 month price targets for Waters in the last 3 months. The average price target is $251.25, with a high forecast of $300.00 and a low forecast of $185.00. The average price target represents a -26.63% upside from the last price of $342.44.

Current Consensus is Hold

The current consensus among 11 polled investment analysts is to hold stock in Waters. This rating has held steady since July 2020, when it changed from a Sell consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

0 strong buy ratings
1 buy ratings
4 hold ratings
4 sell ratings

Ratings as of

12/29/2019

0 strong buy ratings
1 buy ratings
4 hold ratings
6 sell ratings

Ratings as of

3/28/2020

0 strong buy ratings
0 buy ratings
4 hold ratings
5 sell ratings

Ratings as of

6/26/2020

0 strong buy ratings
0 buy ratings
5 hold ratings
5 sell ratings

Ratings as of

9/24/2020

0 strong buy ratings
1 buy ratings
8 hold ratings
5 sell ratings

Ratings as of

12/23/2020

0 strong buy ratings
1 buy ratings
8 hold ratings
5 sell ratings

Ratings as of

3/23/2021

0 strong buy ratings
1 buy ratings
7 hold ratings
3 sell ratings

Ratings as of

5/22/2021

0 strong buy ratings
1 buy ratings
7 hold ratings
3 sell ratings

Ratings as of

6/21/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/6/2021	SVB Leerink	Boost Price Target	Market Perform	$290.00 ➝ $300.00	Low
5/6/2021	Wells Fargo & Company	Boost Price Target	Underweight	$280.00 ➝ $290.00	Low
2/3/2021	Citigroup	Boost Price Target		$250.00 ➝ $300.00	Low
1/7/2021	Wells Fargo & Company	Downgrade	Equal Weight ➝ Underweight	$235.00	N/A
12/17/2020	Cleveland Research	Upgrade	Underperform ➝ Buy		Low
12/16/2020	Smith Barney Citigroup	Upgrade	Sell ➝ Neutral		Low
12/16/2020	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Upgrade	Sell ➝ Neutral	$185.00 ➝ $240.00	N/A
12/2/2020	The Goldman Sachs Group	Initiated Coverage	Neutral	$230.00	Low
11/9/2020	KeyCorp	Initiated Coverage	Sector Weight ➝ Sector Weight	$235.00	Medium
10/28/2020	Stifel Nicolaus	Boost Price Target	Hold	$220.00 ➝ $230.00	Medium
10/28/2020	Smith Barney Citigroup	Boost Price Target		$180.00 ➝ $185.00	Low
10/28/2020	Wells Fargo & Company	Boost Price Target	Equal Weight	$230.00 ➝ $235.00	Low
10/28/2020	SVB Leerink	Boost Price Target	Market Perform	$225.00 ➝ $230.00	Low
7/29/2020	Stifel Nicolaus	Boost Price Target	Hold	$180.00 ➝ $220.00	High
7/29/2020	SVB Leerink	Boost Price Target	Market Perform	$195.00 ➝ $225.00	High
7/29/2020	Citigroup	Boost Price Target	Sell	$150.00 ➝ $180.00	High
7/28/2020	Needham & Company LLC	Initiated Coverage	Sell		High
7/28/2020	JPMorgan Chase & Co.	Upgrade	Underweight ➝ Neutral		Low
7/16/2020	Wells Fargo & Company	Upgrade	Underweight ➝ Equal Weight	$175.00 ➝ $225.00	Medium
4/29/2020	Bank of America	Lower Price Target	Underperform	$160.00 ➝ $145.00	High
4/29/2020	Stifel Nicolaus	Boost Price Target	Hold	$176.00 ➝ $180.00	Medium
4/29/2020	SVB Leerink	Lower Price Target	Market Perform	$210.00 ➝ $195.00	High
4/28/2020	Needham & Company LLC	Initiated Coverage	Sell		High
4/28/2020	UBS Group	Lower Price Target	Neutral	$223.00 ➝ $212.00	Low
4/2/2020	Stifel Nicolaus	Lower Price Target	Hold	$210.00 ➝ $176.00	Low
3/30/2020	Wells Fargo & Company	Lower Price Target	Underweight	$210.00 ➝ $180.00	Medium
3/26/2020	Barclays	Lower Price Target	Underweight	$186.00 ➝ $172.00	High
3/20/2020	Citigroup	Lower Price Target	Sell	$190.00 ➝ $150.00	Medium
2/4/2020	Needham & Company LLC	Reiterated Rating	Sell		High
1/8/2020	Needham & Company LLC	Downgrade	Hold ➝ Underperform		Medium
1/7/2020	Wells Fargo & Company	Initiated Coverage	Underweight	$215.00	High
1/6/2020	Citigroup	Initiated Coverage	Sell	$190.00	Medium
1/3/2020	Needham & Company LLC	Initiated Coverage	Hold	$177.00	Medium
1/3/2020	Bank of America	Upgrade	Underperform ➝ Neutral		Medium
12/4/2019	BTIG Research	Downgrade	Buy ➝ Neutral		Low
11/14/2019	Stifel Nicolaus	Initiated Coverage	Hold	$210.00	Medium
10/29/2019	Needham & Company LLC	Reiterated Rating	Hold		High
10/9/2019	Barclays	Downgrade	Equal Weight ➝ Underweight	$210.00 ➝ $195.00	Low
7/16/2019	Bank of America	Downgrade	Neutral ➝ Underperform		Low
6/12/2019	Cleveland Research	Downgrade	Neutral ➝ Underperform		Medium
5/30/2019	Wolfe Research	Initiated Coverage	Underperform ➝ Underperform		Low
4/24/2019	UBS Group	Lower Price Target	Neutral ➝ Neutral	$248.00 ➝ $230.00	Low
4/24/2019	Robert W. Baird	Lower Price Target	Neutral ➝ Neutral	$211.00 ➝ $209.00	Low
4/24/2019	Barclays	Lower Price Target	Equal Weight ➝ Equal Weight	$218.00 ➝ $210.00	Low
1/25/2019	Barclays	Reiterated Rating	Hold	$200.00	Medium
1/24/2019	BTIG Research	Boost Price Target	Buy	$260.00	Medium
1/24/2019	Robert W. Baird	Downgrade	Outperform ➝ Neutral	$191.00 ➝ $211.00	Medium
1/3/2019	Bank of America	Upgrade	Underperform ➝ Neutral		High
1/2/2019	Needham & Company LLC	Initiated Coverage	Hold ➝ Hold	$177.00	High
12/12/2018	JPMorgan Chase & Co.	Downgrade	Neutral ➝ Underweight	$185.00 ➝ $180.00	Low
12/9/2018	The Goldman Sachs Group	Downgrade	Neutral ➝ Sell	$200.83	Low
11/30/2018	The Goldman Sachs Group	Downgrade	Neutral ➝ Sell	$185.00 ➝ $180.00	Medium
10/24/2018	UBS Group	Lower Price Target	Neutral ➝ Neutral	$210.00 ➝ $200.00	High
10/24/2018	Barclays	Lower Price Target	Equal Weight ➝ Equal Weight	$200.00 ➝ $190.00	High
10/24/2018	JPMorgan Chase & Co.	Lower Price Target	Neutral ➝ Neutral	$200.00 ➝ $185.00	High
10/11/2018	Cleveland Research	Upgrade	Sell ➝ Neutral		High
10/10/2018	Morgan Stanley	Boost Price Target	Equal Weight ➝ Equal Weight	$204.00 ➝ $211.00	Medium
10/9/2018	UBS Group	Initiated Coverage	Neutral ➝ Neutral	$210.00	Low
10/8/2018	SVB Leerink	Downgrade	Outperform ➝ Market Perform		High
7/25/2018	Robert W. Baird	Boost Price Target	Outperform ➝ Outperform	$201.00 ➝ $212.00	Medium
7/25/2018	Morgan Stanley	Lower Price Target	Equal Weight ➝ Equal Weight	$205.00 ➝ $204.00	Low
7/17/2018	Janney Montgomery Scott	Downgrade	Buy ➝ Neutral	$230.00 ➝ $211.00	Medium
7/16/2018	Bank of America	Downgrade	Neutral ➝ Underperform	$190.00	Medium
7/13/2018	Morgan Stanley	Boost Price Target	Equal Weight	$200.00 ➝ $205.00	High
6/14/2018	Cleveland Research	Downgrade	Neutral ➝ Underperform		Medium
4/25/2018	Barclays	Lower Price Target	Equal Weight ➝ Equal Weight	$208.00 ➝ $200.00	Medium
4/25/2018	Morgan Stanley	Lower Price Target	Equal Weight ➝ Equal Weight	$218.00 ➝ $200.00	Low
4/25/2018	Robert W. Baird	Lower Price Target	Outperform ➝ Outperform	$220.00 ➝ $201.00	Low
4/25/2018	Jefferies Financial Group	Reiterated Rating	Hold	$200.00	Medium
4/25/2018	SVB Leerink	Set Price Target	Buy	$230.00 ➝ $214.00	Medium
4/25/2018	Cowen	Reiterated Rating	Hold	$215.00	Medium
4/11/2018	Morgan Stanley	Lower Price Target	Equal Weight ➝ Equal Weight	$237.00 ➝ $218.00	Low
1/25/2018	BTIG Research	Reiterated Rating	Buy		Low
1/24/2018	Barclays	Boost Price Target	Equal Weight ➝ Equal Weight	$202.00 ➝ $208.00	N/A
1/24/2018	Janney Montgomery Scott	Boost Price Target	Buy ➝ Buy	$200.00 ➝ $230.00	N/A
1/24/2018	JPMorgan Chase & Co.	Boost Price Target	Neutral ➝ Neutral	$180.00 ➝ $200.00	N/A
1/24/2018	Robert W. Baird	Boost Price Target	Outperform ➝ Outperform	$219.00 ➝ $220.00	N/A
1/24/2018	Citigroup	Boost Price Target	Neutral ➝ Neutral	$190.00 ➝ $223.00	N/A
1/23/2018	William Blair	Reiterated Rating	Outperform		Low
1/8/2018	Barclays	Reiterated Rating	Hold	$202.00	Medium
1/5/2018	BTIG Research	Initiated Coverage	Buy ➝ Buy	$230.00	Medium
1/3/2018	Evercore ISI	Initiated Coverage	In-Line	$198.00	Medium
12/4/2017	Morgan Stanley	Upgrade	Underweight ➝ Equal Weight	$192.00	High
11/10/2017	Bank of America	Boost Price Target	Neutral	$192.00 ➝ $202.00	N/A
11/3/2017	Cowen	Reiterated Rating	Hold	$190.00	N/A
10/25/2017	Citigroup	Reiterated Rating	Neutral	$180.00	N/A
10/25/2017	Barclays	Boost Price Target	Equal Weight	$188.00 ➝ $193.00	N/A
10/25/2017	Deutsche Bank Aktiengesellschaft	Boost Price Target	Hold	$199.00 ➝ $200.00	N/A
10/25/2017	Robert W. Baird	Boost Price Target	Outperform	$196.00 ➝ $199.00	N/A
10/9/2017	Cleveland Research	Downgrade	Buy ➝ Neutral		N/A
10/6/2017	Morgan Stanley	Reiterated Rating	Underweight ➝ Underweight	$183.00 ➝ $192.00	N/A
9/26/2017	The Goldman Sachs Group	Initiated Coverage	Hold	$180.00	Low
8/31/2017	Jefferies Financial Group	Reiterated Rating	Hold	$175.00	Low
7/27/2017	Jefferies Financial Group	Reiterated Rating	Hold	$175.00	Low
7/26/2017	Morgan Stanley	Reiterated Rating	Underweight	$174.00 ➝ $183.00	Low
7/21/2017	Bank of America	Reiterated Rating	Neutral	$180.00 ➝ $192.00	Low
7/14/2017	Cowen	Reiterated Rating	Hold	$190.00	Medium
7/14/2017	Jefferies Financial Group	Reiterated Rating	Hold	$170.00	Low
7/13/2017	Wells Fargo & Company	Reiterated Rating	Outperform	$195.00 ➝ $205.00	Low
7/10/2017	Deutsche Bank Aktiengesellschaft	Downgrade	Buy ➝ Hold	$183.00 ➝ $194.00	High
5/1/2017	Janney Montgomery Scott	Upgrade	Neutral ➝ Buy	$185.00 ➝ $200.00	Medium
4/29/2017	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Buy	$166.00 ➝ $183.00	Medium
4/26/2017	Barclays	Set Price Target	Hold	$160.00	Low
4/26/2017	Cowen	Boost Price Target	Market Perform	$160.00 ➝ $175.00	Low
4/25/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$170.00 ➝ $190.00	Low
3/3/2017	Evercore ISI	Downgrade	Hold ➝ Underperform		N/A
3/3/2017	Jefferies Financial Group	Boost Price Target	Hold	$147.00 ➝ $150.00	N/A
3/3/2017	Cantor Fitzgerald	Reiterated Rating	Overweight	$170.00	N/A
1/24/2017	Cantor Fitzgerald	Set Price Target	Buy	$170.00	N/A
1/18/2017	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Buy	$160.00	N/A
1/9/2017	Barclays	Reiterated Rating	Hold	$148.00	N/A
1/6/2017	William Blair	Upgrade	Market Perform ➝ Outperform		N/A
12/8/2016	Cantor Fitzgerald	Set Price Target	Buy	$170.00	N/A
11/10/2016	SVB Leerink	Reiterated Rating	Outperform	$163.00	N/A
10/28/2016	Jefferies Financial Group	Reiterated Rating	Hold	$150.00 ➝ $145.00	N/A
10/25/2016	Cantor Fitzgerald	Reiterated Rating	Buy	$170.00	N/A
7/27/2016	Citigroup	Boost Price Target	Neutral	$138.00 ➝ $160.00	N/A
7/27/2016	Barclays	Boost Price Target	Equal Weight	$130.00 ➝ $157.00	N/A
7/27/2016	Jefferies Financial Group	Boost Price Target	Hold	$128.00 ➝ $150.00	N/A
7/27/2016	Mizuho	Boost Price Target	Neutral	$130.00 ➝ $145.00	N/A
7/26/2016	Evercore ISI	Boost Price Target	Hold	$140.50 ➝ $154.00	N/A
7/26/2016	Cantor Fitzgerald	Boost Price Target	Buy	$163.00 ➝ $173.00	N/A

(Data available from 6/21/2016 forward)

Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company's offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company has a collaboration with Genovis AB to develop and market biopharmaceutical characterization workflows based on the its BioAccord LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.

Today's Range

Now: $342.44

$341.09

$345.90

50 Day Range

MA: $314.40

$296.27

$346.56

52 Week Range

Now: $342.44

$171.38

$348.10

Volume

484,459 shs

Average Volume

388,471 shs

Market Capitalization

$21.13 billion

P/E Ratio

34.70

Dividend Yield

N/A

Beta

0.8

Frequently Asked Questions

What sell-side analysts currently cover shares of Waters?

The following Wall Street sell-side analysts have issued stock ratings on Waters in the last twelve months: Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Cleveland Research, JPMorgan Chase & Co., KeyCorp, Needham & Company LLC, Smith Barney Citigroup, Stifel Nicolaus, SVB Leerink LLC, The Goldman Sachs Group, Inc., TheStreet, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for WAT.

What is the current price target for Waters?

8 Wall Street analysts have set twelve-month price targets for Waters in the last year. Their average twelve-month price target is $251.25, suggesting a possible downside of 26.7%. SVB Leerink LLC has the highest price target set, predicting WAT will reach $300.00 in the next twelve months. Smith Barney Citigroup has the lowest price target set, forecasting a price of $185.00 for Waters in the next year.
View the latest price targets for WAT.

What is the current consensus analyst rating for Waters?

Waters currently has 3 sell ratings, 7 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in WAT, but not buy more shares or sell existing shares.
View the latest ratings for WAT.

What other companies compete with Waters?

Other companies that are similar to Waters include Thermo Fisher Scientific, Illumina, Agilent Technologies, Mettler-Toledo International, Bio-Rad Laboratories, Charles River Laboratories International, PerkinElmer, Bio-Techne, Bruker, Pacific Biosciences of California, Luminex, Fluidigm, Harvard Bioscience, aTyr Pharma and BG Medicine.

How do I contact Waters' investor relations team?

Waters' physical mailing address is 34 MAPLE STREET, MILFORD MA, 01757. The medical instruments supplier's listed phone number is 508-478-2000 and its investor relations email address is [email protected] The official website for Waters is www.waters.com.